Conditions: Ocular Hypertension Glaucoma
Keywords: Ocular hypertension. Glaucoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 93
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.

Detailed description:

Arms:
arm 1: 1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU) arm 2: 1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU) arm 3: 1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)

Interventions: intervention 1: AR-13324 Ophthalmic Solution 0.02% intervention 2: AR-13324 Ophthalmic Solution 0.02% BID intervention 3: Timolol maleate Ophthalmic Solution 0.5% BID intervention 4: Placebo
Intervention descriptions: intervention 1: 1 drop once daily (QD), PM, OU intervention 2: 1 drop BID, AM/PM, OU intervention 3: 1 drop BID, AM/PM, OU intervention 4: 1 drop QD, AM, OU

Protocol document: